HK1210153A1 - Compound for preparing an intermediate compound of optically-active diazabicyclooctane derivative - Google Patents

Compound for preparing an intermediate compound of optically-active diazabicyclooctane derivative

Info

Publication number
HK1210153A1
HK1210153A1 HK15110896.7A HK15110896A HK1210153A1 HK 1210153 A1 HK1210153 A1 HK 1210153A1 HK 15110896 A HK15110896 A HK 15110896A HK 1210153 A1 HK1210153 A1 HK 1210153A1
Authority
HK
Hong Kong
Prior art keywords
compound
optically
preparing
diazabicyclooctane derivative
active diazabicyclooctane
Prior art date
Application number
HK15110896.7A
Other languages
English (en)
Chinese (zh)
Inventor
阿部隆夫
奧江雅之
坂卷儀晃
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of HK1210153A1 publication Critical patent/HK1210153A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15110896.7A 2010-12-22 2015-11-04 Compound for preparing an intermediate compound of optically-active diazabicyclooctane derivative HK1210153A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010073093 2010-12-22

Publications (1)

Publication Number Publication Date
HK1210153A1 true HK1210153A1 (en) 2016-04-15

Family

ID=46313528

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110896.7A HK1210153A1 (en) 2010-12-22 2015-11-04 Compound for preparing an intermediate compound of optically-active diazabicyclooctane derivative

Country Status (18)

Country Link
EP (1) EP2657234B1 (fr)
JP (3) JP5903386B2 (fr)
KR (1) KR101836554B1 (fr)
CN (2) CN104892490B (fr)
AR (1) AR116907A2 (fr)
AU (2) AU2011346224B2 (fr)
CA (1) CA2822758C (fr)
DK (1) DK2657234T3 (fr)
ES (1) ES2622004T3 (fr)
HK (1) HK1210153A1 (fr)
HU (1) HUE032491T2 (fr)
IL (5) IL227087A0 (fr)
PL (1) PL2657234T3 (fr)
RU (1) RU2591701C2 (fr)
SG (2) SG191320A1 (fr)
SI (1) SI2657234T1 (fr)
TW (1) TWI599355B (fr)
WO (1) WO2012086241A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822758C (fr) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Derive de diazabicyclooctane optiquement actif et son procede de preparation
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
BR112013032415B1 (pt) * 2011-06-17 2021-07-27 Pfizer Anti-Infectives Ab Processos para preparar compostos e compostos
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2013149136A1 (fr) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Inhibiteurs des β-lactamases dérivés d'isoxazole
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
EP2915805A4 (fr) * 2012-11-01 2016-03-23 Kaneka Corp Procédé pour la production d'un composé d'urée bicyclique optiquement actif
US9862718B2 (en) * 2013-03-08 2018-01-09 Wockhardt Limited Sodium salt of (2S, 5R)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1] octane-2-carboxylic acid and its preparation
WO2014135932A1 (fr) * 2013-03-08 2014-09-12 Wockhardt Limited Procédé de préparation de (2s, 5r)-7-oxo-6-sulfoxy-2-[((3r)- pyrrolidine- 3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]octane
JP6182621B2 (ja) * 2013-03-08 2017-08-16 ウォックハート リミテッド （２ｓ，５ｒ）−硫酸モノ−｛［（４−アミノピペリジン−４−イル）カルボニル］−７−オキソ−１，６−ジアザ−ビシクロ［３．２．１］オクタ−６−イル｝エステルを調製するための方法
WO2014135930A1 (fr) * 2013-03-08 2014-09-12 Wockhardt Limited Procédé pour sel de sodium de (2s, 5r)-2-carboxamido -7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2014135931A1 (fr) * 2013-03-08 2014-09-12 Wockhardt Limited Procédé pour la préparation du (2s, 5r)-7-oxo-6-sulfo-oxy-2-[((3r)-pipéridine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
JP6285969B2 (ja) 2013-03-08 2018-02-28 ウォックハート リミテッド （２ｓ，５ｒ）−７−オキソ−６−スルホオキシ−２−［（（３ｒ）−ピペリジン−３−カルボニル）−ヒドラジノカルボニル］−１，６−ジアザ−ビシクロ［３．２．１］オクタンの調製のためのプロセス
WO2014152996A1 (fr) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Forme cristalline d'un inhibiteur de bêta-lactamase
JP6453222B2 (ja) * 2013-09-24 2019-01-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
WO2015051101A1 (fr) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. Sel picoline inhibiteur de b-lactamase
HUE051925T2 (hu) 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
CN105980385B (zh) * 2014-02-03 2018-01-09 沃克哈特有限公司 制备(2s,5r)‑1,6‑二氮杂‑二环[3.2.1]辛烷‑2‑腈‑7‑氧代‑6‑(磺氧基)‑单钠盐的方法
IN2014MU01192A (fr) * 2014-03-29 2015-10-02 Wockhardt Ltd
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
EP3334734B1 (fr) * 2015-08-10 2020-01-01 Sandoz AG Forme c d'avibactam sodique
CN107325096B (zh) * 2016-04-29 2020-11-03 正大天晴药业集团股份有限公司 一种阿维巴坦单钠盐的结晶
CN106565712A (zh) * 2016-09-30 2017-04-19 天津津泰生物医药技术有限公司 一种阿维巴坦钠中间体的制备方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN106866668B (zh) * 2017-01-23 2019-01-11 齐鲁天和惠世制药有限公司 一锅法制备阿维巴坦钠的方法
CN106831772B (zh) * 2017-03-04 2019-12-17 丽珠医药集团股份有限公司 一种阿维巴坦中间体的合成方法
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018234962A1 (fr) * 2017-06-20 2018-12-27 Wockhardt Limited Procédé de o-sulfonation de composés 1,6-diazabicyclo[3.2.1]octane
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
CN107417686B (zh) * 2017-09-19 2020-04-28 北京化工大学 一种阿维巴坦钠的合成方法
CA3077474A1 (fr) 2017-10-02 2019-04-11 Arixa Pharmaceuticals, Inc. Derives d'aztreonam et utilisations associees
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109678855B (zh) 2017-10-18 2020-07-17 新发药业有限公司 一种阿维巴坦中间体的制备方法
CA3205816A1 (fr) 2017-11-03 2019-05-09 Alcon Inc. Derives d'azabicyclo et de diazepine pour le traitement de troubles oculaires
CN107941969B (zh) * 2017-11-07 2021-03-02 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酰胺的检测方法
CN107907604B (zh) * 2017-11-07 2021-01-22 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107894471A (zh) * 2017-11-07 2018-04-10 中山奕安泰医药科技有限公司 一种阿维巴坦钠中间体的检测方法
WO2019093450A1 (fr) * 2017-11-10 2019-05-16 塩野義製薬株式会社 Dérivé de diazabicyclooctane
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
ES2928152T3 (es) 2017-12-01 2022-11-15 Qilu Pharmaceutical Co Ltd Forma cristalina de un inhibidor de beta-lactamasa y método de preparación de la misma
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN109970625B (zh) * 2017-12-28 2021-02-26 新发药业有限公司 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN112930338A (zh) * 2018-09-21 2021-06-08 株式会社Api 氨基酸衍生物的制备方法
JP7437847B2 (ja) 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド レレバクタムの誘導体およびその使用
JP2022524118A (ja) 2019-03-12 2022-04-27 アリクサ ファーマシューティカルズ、インコーポレイテッド アビバクタム誘導体の結晶形
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
CN111777607A (zh) * 2020-07-21 2020-10-16 海南海灵化学制药有限公司 一种阿维巴坦纳的制备方法
CN116375706A (zh) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124014C1 (ru) * 1993-12-29 1998-12-27 Пфайзер Инк. Диазабициклические соединения и содержащая их фармацевтическая композиция
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (fr) 2008-06-19 2017-12-27 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CA2822758C (fr) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Derive de diazabicyclooctane optiquement actif et son procede de preparation

Also Published As

Publication number Publication date
CA2822758A1 (fr) 2012-06-28
KR101836554B1 (ko) 2018-04-19
RU2013133870A (ru) 2015-01-27
IL227087A0 (en) 2016-10-31
PL2657234T3 (pl) 2017-06-30
ES2622004T3 (es) 2017-07-05
IL244239A0 (en) 2016-04-21
HUE032491T2 (en) 2017-09-28
CN103328476A (zh) 2013-09-25
IL248246A0 (en) 2016-11-30
AR116907A2 (es) 2021-06-23
EP2657234A4 (fr) 2014-10-08
IL238032A (en) 2017-05-29
JP2016117742A (ja) 2016-06-30
JP5903386B2 (ja) 2016-04-13
EP2657234A1 (fr) 2013-10-30
CA2822758C (fr) 2018-03-20
CN104892490A (zh) 2015-09-09
JP2018009008A (ja) 2018-01-18
SG10201510576WA (en) 2016-01-28
JPWO2012086241A1 (ja) 2014-05-22
IL248246B (en) 2021-02-28
AU2011346224B2 (en) 2017-04-06
AU2017203187B2 (en) 2018-07-26
AU2017203187A1 (en) 2017-06-01
RU2591701C2 (ru) 2016-07-20
CN103328476B (zh) 2016-12-28
EP2657234B1 (fr) 2017-01-11
AU2011346224A1 (en) 2013-07-04
JP6364431B2 (ja) 2018-07-25
DK2657234T3 (da) 2017-02-20
IL244239B (en) 2019-01-31
TWI599355B (zh) 2017-09-21
SG191320A1 (en) 2013-07-31
TW201225958A (en) 2012-07-01
KR20140040688A (ko) 2014-04-03
IL243939A0 (en) 2016-04-21
SI2657234T1 (sl) 2017-06-30
WO2012086241A1 (fr) 2012-06-28
CN104892490B (zh) 2017-07-21

Similar Documents

Publication Publication Date Title
HK1210153A1 (en) Compound for preparing an intermediate compound of optically-active diazabicyclooctane derivative
TWI561518B (en) Method of preparing an indole compound
IL243021B (en) A method for preparing multicyclic components
HK1203192A1 (en) Method of preparation of enantiomers of spiro-oxindole compounds
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2609120A4 (fr) Procédé amélioré de préparation de sugammadex
IL221170A0 (en) Processes of synthesizing dihydropyridophthalazinone derivatives
EP2582707A4 (fr) Formes polymorphiques de rifaximine
SG2014013460A (en) Monohydrate of an azaadamantane derivative
AP3270A (en) Production method of intermediate compound for synthesizing medicament
IL222313A0 (en) Combination of organic compounds
IL222474A0 (en) Method of synthesis
HK1185081A1 (en) Cyclohexane derivative compound
EP2680843A4 (fr) Dérivés de composés amino-hétéroaryles substitués par des pyrazoles
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
HK1171020A1 (en) Process for preparation of pyrimidinylpyrazole compounds
EP2537851A4 (fr) Procédé de préparation de composés b-glycosides
GB2483682B (en) Method of securing fitted furniture
EP2578568A4 (fr) Procédé de préparation de dérivés de 4 fluoropyrrolidine substitués en 3
EP2563748A4 (fr) Procédé de préparation d'un composé alcène
IL243319A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
GB201108346D0 (en) Polymorphic form of compound
EP2546235A4 (fr) PROCÉDÉ DE PRÉPARATION DE COMPOSÉS t-BUTOXYCARBONYLAMINES
GB201108347D0 (en) Polymprphic form of compound
TWM388841U (en) Positioning assembly of rotational wheel for pets